What is Medtronic Plc share price today?

Medtronic Plc (MDT) share price today is {{live_price}}.

Can Indians buy Medtronic Plc shares?

Yes, Indians can invest in the Medtronic Plc (MDT) from India. With INDmoney, you can buy Medtronic Plc at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Medtronic Plc at zero transaction cost.

How can I buy Medtronic Plc shares from India?

It is very easy to buy Medtronic Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Medtronic Plc be purchased?

Yes, you can buy fractional shares of Medtronic Plc with INDmoney app.

What are the documents required to start investing in Medtronic Plc stocks?

To start investing in Medtronic Plc, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Medtronic Plc

Today’s highest price of Medtronic Plc (MDT) is {{1_rba_end}}. Today’s lowest price of Medtronic Plc (MDT) is {{1_rba_st}}.

What is today's market capitalisation of Medtronic Plc

Today's market capitalisation of Medtronic Plc MDT is 110.3B

What is the 52 Week High and Low Range of Medtronic Plc

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Medtronic Plc is down from its 52 Week High?

Medtronic Plc (MDT) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Medtronic Plc is up from its 52 Week low?

Medtronic Plc (MDT) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Medtronic Plc?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Medtronic Plc

Mr. Geoffrey Straub Martha is the current Chief Executive Officer (CEO) of Medtronic Plc.

Home>
US Stocks>
Medtronic Plc

Medtronic Plc (MDT)

$84.74

+0.63

(+0.75%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Medtronic PLC is a global medical device company that provides innovative solutions to improve patient outcomes and reduce healthcare costs.

Performance

$83.92
$85.12
$84.74
0.97%
Downside
Day's Volatility :1.41%
Upside
0.45%
$75.96
$92.68
$84.74
10.36%
Downside
52 Weeks Volatility :18.04%
Upside
8.57%

Returns

Period	Medtronic Plc	Sector (Health Care)	S&P500
3 Months	-3.52%	-6.9%	6.8%
6 Months	-1.19%	-1.7%	12.1%
1 Year	8.13%	10.4%	30.6%
3 Years	-27.5%	8.8%	27.0%

Highlights

Market Capitalization	110.3B
Book Value	$37.39
Dividend Share	2.77
Dividend Yield	3.18%
Earnings Per Share (EPS)	2.91
PE Ratio	29.55
PEG Ratio	1.63
Wall Street Target Price	96.224

Profit Margin	12.06%
Operating Margin TTM	17.51%

Return On Assets TTM	4.42%
Return On Equity TTM	7.95%

Revenue TTM	32.6B
Revenue Per Share TTM	24.71
Quarterly Revenue Growth YOY	2.8000000000000003%
Gross Profit TTM	21.7B
EBITDA	9.0B
Diluted Eps TTM	2.91
Quarterly Earnings Growth YOY	0.36

EPS Estimate Current Year	5.2
EPS Estimate Next Year	5.45
EPS Estimate Current Quarter	1.2
EPS Estimate Next Quarter	0.0

Analyst Recommendation

Buy

51%Buy

43%Hold

5%Sell

Based on 37 Wall street analysts offering stock ratings for Medtronic Plc(by analysts ranked 0 to 5 stars)

Based on 37 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 13.55%

Current $84.74

Target $96.22

Company Financials

	FY19	Y/Y Change
Revenue	30.6B	↑ 2.02%
Net Income	4.6B	↑ 49.19%
Net Profit Margin	15.16%	↑ 4.8%

	FY20	Y/Y Change
Revenue	28.9B	↓ 5.38%
Net Income	4.8B	↑ 3.41%
Net Profit Margin	16.56%	↑ 1.4%

	FY21	Y/Y Change
Revenue	30.1B	↑ 4.16%
Net Income	3.6B	↓ 24.7%
Net Profit Margin	11.97%	↓ 4.59%

	FY22	Y/Y Change
Revenue	31.7B	↑ 5.21%
Net Income	5.0B	↑ 39.74%
Net Profit Margin	15.9%	↑ 3.93%

	FY23	Y/Y Change
Revenue	31.2B	↓ 1.45%
Net Income	3.8B	↓ 25.42%
Net Profit Margin	12.03%	↓ 3.87%

	FY24	Y/Y Change
Revenue	32.4B	↑ 3.64%
Net Income	3.7B	↓ 2.18%
Net Profit Margin	11.36%	↓ 0.67%

	Q2 FY23	Q/Q Change
Revenue	8.5B	↑ 10.57%
Net Income	1.2B	↓ 3.52%
Net Profit Margin	13.8%	↓ 2.01%

	Q3 FY23	Q/Q Change
Revenue	7.7B	↓ 9.85%
Net Income	791.0M	↓ 32.91%
Net Profit Margin	10.27%	↓ 3.53%

	Q4 FY23	Q/Q Change
Revenue	8.0B	↑ 3.66%
Net Income	909.0M	↑ 14.92%
Net Profit Margin	11.39%	↑ 1.12%

	Q1 FY24	Q/Q Change
Revenue	8.1B	↑ 1.32%
Net Income	1.3B	↑ 45.43%
Net Profit Margin	16.34%	↑ 4.95%

	Q2 FY24	Q/Q Change
Revenue	8.6B	↑ 6.18%
Net Income	654.0M	↓ 50.53%
Net Profit Margin	7.61%	↓ 8.73%

	Q3 FY24	Q/Q Change
Revenue	7.9B	↓ 7.85%
Net Income	1.0B	↑ 59.33%
Net Profit Margin	13.16%	↑ 5.55%

	FY19	Y/Y Change
Total Assets	89.7B	↓ 1.86%
Total Liabilities	39.5B	↓ 2.68%

	FY20	Y/Y Change
Total Assets	90.7B	↑ 1.11%
Total Liabilities	39.8B	↑ 0.85%

	FY21	Y/Y Change
Total Assets	93.1B	↑ 2.64%
Total Liabilities	41.5B	↑ 4.18%

	FY22	Y/Y Change
Total Assets	91.0B	↓ 2.26%
Total Liabilities	38.3B	↓ 7.77%

	FY23	Y/Y Change
Total Assets	90.9B	↓ 0.04%
Total Liabilities	39.3B	↑ 2.68%

	FY24	Y/Y Change
Total Assets	90.0B	↓ 1.06%
Total Liabilities	39.6B	↑ 0.71%

	Q2 FY23	Q/Q Change
Total Assets	90.9B	↓ 3.38%
Total Liabilities	39.3B	↓ 7.6%

	Q3 FY23	Q/Q Change
Total Assets	90.8B	↓ 0.19%
Total Liabilities	39.4B	↑ 0.32%

	Q4 FY23	Q/Q Change
Total Assets	90.1B	↓ 0.76%
Total Liabilities	38.4B	↓ 2.46%

	Q1 FY24	Q/Q Change
Total Assets	90.8B	↑ 0.83%
Total Liabilities	38.8B	↑ 1.04%

	Q2 FY24	Q/Q Change
Total Assets	90.0B	↓ 0.94%
Total Liabilities	39.6B	↑ 1.85%

	Q3 FY24	Q/Q Change
Total Assets	89.7B	↓ 0.26%
Total Liabilities	41.6B	↑ 5.13%

	FY19	Y/Y Change
Operating Cash Flow	7.0B	↑ 49.59%
Investing Cash Flow	-774.0M	↓ 113.21%
Financing Cash Flow	-5.4B	↓ 54.57%

	FY20	Y/Y Change
Operating Cash Flow	7.2B	↑ 3.24%
Investing Cash Flow	-3.2B	↑ 313.82%
Financing Cash Flow	-4.2B	↓ 22.7%

	FY21	Y/Y Change
Operating Cash Flow	6.2B	↓ 13.74%
Investing Cash Flow	-2.9B	↓ 10.52%
Financing Cash Flow	-4.1B	↓ 1.48%

	FY22	Y/Y Change
Operating Cash Flow	7.3B	↑ 17.72%
Investing Cash Flow	-1.7B	↓ 42.11%
Financing Cash Flow	-5.3B	↑ 29.01%

	FY23	Y/Y Change
Operating Cash Flow	6.0B	↓ 17.79%
Investing Cash Flow	-3.5B	↑ 110.55%
Financing Cash Flow	-5.0B	↓ 7.05%

	Q2 FY23	Q/Q Change
Operating Cash Flow	2.5B	↑ 56.29%
Investing Cash Flow	-475.0M	↓ 84.26%
Financing Cash Flow	-4.9B	↑ 129.15%

	Q3 FY23	Q/Q Change
Operating Cash Flow	875.0M	↓ 64.43%
Investing Cash Flow	-539.0M	↑ 13.47%
Financing Cash Flow	-501.0M	↓ 89.75%

	Q4 FY23	Q/Q Change
Operating Cash Flow	661.0M	↓ 24.46%
Investing Cash Flow	-424.0M	↓ 21.34%
Financing Cash Flow	-90.0M	↓ 82.04%

Technicals Summary

Sell

Neutral

Buy

Medtronic Plc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Medtronic Plc	-7.0%	-1.19%	8.13%	-27.5%	-23.53%
Stryker Corporation	6.59%	16.31%	32.68%	49.88%	93.53%
Boston Scientific Corp.	3.97%	21.4%	65.07%	124.82%	118.64%
Edwards Lifesciences Corp.	1.65%	-21.98%	4.95%	-38.71%	-12.32%
Abbott Laboratories	0.98%	11.87%	14.18%	-6.39%	40.03%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Medtronic Plc	29.55	29.55	1.63	5.2	0.08	0.04	0.03	37.39
Stryker Corporation	41.34	41.34	2.69	12.05	0.19	0.07	0.01	52.86
Boston Scientific Corp.	74.52	74.52	1.64	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	27.17	27.17	6.38	2.53	0.19	0.11	NA	16.18
Abbott Laboratories	35.56	35.56	2.25	4.68	0.15	0.06	0.02	22.94

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Medtronic Plc	Buy	$110.3B	-23.53%	29.55	12.06%
Stryker Corporation	Buy	$147.0B	93.53%	41.34	16.34%
Boston Scientific Corp.	Buy	$132.9B	118.64%	74.52	11.26%
Edwards Lifesciences Corp.	Buy	$41.5B	-12.32%	27.17	65.86%
Abbott Laboratories	Buy	$203.2B	40.03%	35.56	13.99%

Insights on Medtronic Plc

Decreasing Revenue
Revenue is down for the last 2 quarters, 8.58B → 7.91B (in $), with an average decrease of 7.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 654.0M → 1.04B (in $), with an average increase of 37.2% per quarter
Vs BSX
In the last 1 year, Boston Scientific Corp. has given 65.1% return, outperforming this stock by 57.0%
Vs BSX
In the last 3 years, Boston Scientific Corp. has given 124.8% return, outperforming this stock by 152.3%

Institutional Holdings

Vanguard Group Inc
9.87%
BlackRock Inc
8.72%
State Street Corp
4.69%
Morgan Stanley - Brokerage Accounts
4.41%
Capital Research Global Investors
2.47%
JPMorgan Chase & Co
2.23%

Corporate Announcements

Medtronic Plc Dividends March,2024
In the quarter ending March,2024. Medtronic Plc has declared dividend of $0.69
Read More

Organization	Medtronic Plc
Employees	95000
CEO	Mr. Geoffrey Straub Martha
Industry	Health Technology

Medtronic Plc (MDT)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Decreasing Revenue

Increasing Net Profit

Vs BSX

Vs BSX

Institutional Holdings

Corporate Announcements

Medtronic Plc Dividends March,2024

Company Information

Discover More

FAQs